Welcome to NLS Pharmaceutics

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Room

Interview with Alex Zwyer, CEO of NLS Pharmaceutics AG (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section

Latest News

  • Aug 13, 2019
    NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity
  • Jul 3, 2019
    NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio
  • Mar 19, 2019
    NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS- 1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®
  • Feb 25, 2019
    NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America
Contact us

NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.

Alter Postplatz 2
CH-6370 Stans NW

T: +41 41 618 80 00
F: +41 41 618 80 09

Your Name (required)

Your Email (required)


Your Message